Previous 10 | Next 10 |
MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the co...
TELA Bio Inc (TELA) Q4 2020 Earnings Conference Call March 24, 2021, 04:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group, IR Antony Koblish - President and CEO Nora Brennan - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Anthony Petrone - J...
TELA Bio (TELA): Q4 GAAP EPS of -$0.54 misses by $0.07.Revenue of $5.67M (+16.7% Y/Y) beats by $0.1M.Cash and cash equivalents on December 31, 2020 were $74.4 million.2021 Outlook: TELA Bio expects total revenue to be in the range of $27.0 million to $30.0 million, representing growth of...
MALVERN, Pa., March 24, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today reported financial re...
MALVERN, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the results...
MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the co...
MALVERN, Pa., Feb. 04, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Com...
TELA Bio (TELA) reports preliminary Q4 and FY 2020 results. Q4 rand FY20 revenue is expected to be $5.5M - $5.7M (consensus $6.03M) and $18.0M - 18.2M (est. $18.52M), respectively.Cash and equivalents at December 31, 2020 is expected to be $74.4M. "Our revenue in the fourth quarter conti...
MALVERN, Pa., Jan. 14, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today r...
MALVERN, Pa., Jan. 06, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that t...
News, Short Squeeze, Breakout and More Instantly...
MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 44 th Annual Growth Con...
MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report second quarter 2024 financial results on Mon...
2024-06-27 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...